Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This letter discusses the limited treatment options for pediatric alopecia areata and the lack of controlled studies for therapies like systemic and off-label immunosuppressive drugs, without reporting new clinical results.

This review explores the Charaka samhita's concept of Ashtanindita purusha, identifying eight physical constitutions traditionally regarded as undesirable due to their association with various diseases, and aims to correlate these with contemporary genetic, endocrinological, and metabolic disorders.

This study found that both tofacitinib and methotrexate effectively reduced hair loss and psychological distress in patients with moderate-to-severe alopecia areata, but tofacitinib showed much greater efficacy. Both treatments had similar safety profiles, with no serious adverse effects reported.

This study reported that the prevalence of atopic dermatitis in cats was higher than previously suggested, with severe nonseasonal pruritus most common, and certain breeds were predisposed.

In a mouse model study, researchers found that mutations in Aire reduced alopecia areata frequency, while Notch4 mutations did not lead to the disease, likely due to proximity with a resistance gene.

This paper reviews the challenges of treating alopecia areata affecting eyelashes and discusses the risks associated with traditional therapies; it reports no new clinical results.

This study suggests that the vitamin D receptor and hairless gene may directly regulate each other via a transcriptional mechanism, potentially explaining phenotypic similarities between atrichia and VDRRIIa rickets.

This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial.

This study observed that vitamin D deficiency in alopecia areata correlates inversely with disease severity and duration, but does not correlate with serum vitamin D levels.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.

In this study, sublingual tofacitinib achieved a longer estimated half-life than oral administration in treatment-resistant alopecia areata patients, potentially supporting daily dosing; overall treatment response was modest.

This study highlights two cases of Mudichood dermatosis in Pune, Maharashtra, suggesting the condition may occur outside its typical geographic range due to hair management practices causing friction.

This study reported that dandelion herb-derived carbon dots significantly enhanced wound healing in mice with Staphylococcus aureus infections, outperforming a commercial wound healing spray through their antibacterial and dual ROS-modulating capabilities.

This study found that the JAK1 inhibitors baricitinib and abrocitinib significantly reduced mechanical alloknesis in a murine model of atopic dermatitis, whereas the JAK2 inhibitor AZ960 had no effect.

This study suggests a new subtype of alopecia, termed 'acute diffuse and total alopecia of the female scalp' (ADTAFS), characterized by acute and total hair loss in women with a favorable recovery profile.

This study indicates that individuals exposed to PPD mount varying immune responses, with either tolerance, subclinical inflammation, or allergy, suggesting no true non-responders to PPD.

This study found that hypaphorine alters cytoskeletal organization in Eucalyptus globulus root hairs, contributing to reduced root hair elongation by possibly disrupting vesicle delivery needed for growth.

This study conducted a meta-analysis and found that among therapies for alopecia areata, baricitinib_4 mg was most likely to be effective, followed by ritlecitinib and ivarmacitinib, while other treatments like dupilumab and secukinumab were less effective.

In a real-world study, baricitinib was effective for scalp, eyebrow, and eyelash regrowth in patients with alopecia areata, showing clinically meaningful improvements as early as 3 months and increasing up to 12 months; satisfaction and perceived improvement were also high among participants.

This report highlights that oral Janus kinase inhibitors, including baricitinib, ritlecitinib, deuruxolitinib, and brepocitinib, show promise for treating alopecia areata by promoting substantial hair regrowth with mild-to-moderate side effects, positioning them as a favorable alternative to corticosteroids.

This source suggests that alitretinoin may be a safe and potentially effective treatment for patients with mild to moderate alopecia areata not responding to conventional therapies, though further research is needed to confirm its role, either alone or as an adjunct.

This paper discusses the concept of "coudability," a characteristic of alopecia areata, and provides a historical perspective, but it reports no new clinical results.

This study documented a case where the medication baricitinib effectively promoted hair regrowth in a woman with alopecia areata but also led to an unexpected side effect of hypertrichosis, suggesting a need to further explore the JAK/STAT pathway's role in hair growth dynamics.

In this study, pediatric alopecia areata was associated with higher rates of vitiligo, asthma, and ADHD, and significantly lower levels of vitamin B12, ferritin, and TSH compared to healthy controls, highlighting the need for comprehensive evaluation.

Enhancing Tregs can protect against alopecia areata.

This review discusses the use of baricitinib in dermatology, emphasizing its effectiveness in treating certain dermatoses, while highlighting the need for awareness of its potential side effects and calling for more long-term safety data.

This article provides a reference guide for various dermatological terms, treatments, and conditions, but reports no new clinical findings.

This study found that C3H mice with prior microbial exposure developed alopecia areata at a reduced rate and had fewer associated T cells compared to controls, suggesting that prior infections might attenuate autoimmune responses related to the disease.

Baricitinib effectively regrew hair in a woman with alopecia universalis after other treatments failed.